2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831
(Norristown, Pennsylvania, USA, 21 August 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that its PluroGel® PN topical antibiotic, utilizing a unique combination of antibiotics in its differentiated and patent protected PluroGel®, has started its USA Phase II clinical trial for infected diabetic foot ulcers. Currently, PluroGen’s research shows that there is no topical antibiotic approved by FDA for the treatment of infections of diabetic foot ulcers. Diabetes is a disease estimated to afflict approximately 28 million people in the US alone. Many diabetics have the additional problem of a chronic condition known as diabetic foot ulcer and patients with diabetic foot ulcer experience a high rate of infection known as diabetic foot infection. Currently, it is thought that approximately 3 million patients per year are treated for diabetic foot infection in the USA. The worldwide market for diabetic foot infection is estimated at approximately $1.5 billion in 2011 with the affliction and market expected to continue growth, driven by the aging population, growing obesity and the increasing diagnosis of diabetes.
“We have achieved another major milestone this summer.” said Neal Koller, President and CEO of PluroGen.
“Beginning the Phase II clinical trial builds on the success of the approximately 12,000 patients treated with the early version of PluroGel® PN at the University of Virginia which supported FDA’s agreement to fast-track our clinical trial plan. The Phase II clinical trial is a big step towards entrance into the USA market, to improve care for patients and to increase shareholder value.”
For Immediate Release
21 August 2013
Contact: Tricia Thompson
+1 (610) 539-3670